Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Application of activated nucleoside analogs for the treatment of drug-resistant tumors by oral delivery of nanogel-drug conjugates.

Senanayake TH, Warren G, Wei X, Vinogradov SV.

J Control Release. 2013 Apr 28;167(2):200-9. doi: 10.1016/j.jconrel.2013.01.020. Epub 2013 Feb 4.

2.

Novel anticancer polymeric conjugates of activated nucleoside analogues.

Senanayake TH, Warren G, Vinogradov SV.

Bioconjug Chem. 2011 Oct 19;22(10):1983-93. doi: 10.1021/bc200173e. Epub 2011 Sep 9.

3.

Efficient overcoming of drug resistance to anticancer nucleoside analogs by nanodelivery of active phosphorylated drugs.

Galmarini CM, Warren G, Senanayake MT, Vinogradov SV.

Int J Pharm. 2010 Aug 16;395(1-2):281-9. doi: 10.1016/j.ijpharm.2010.05.028. Epub 2010 May 24.

4.

Polymeric nanogels containing the triphosphate form of cytotoxic nucleoside analogues show antitumor activity against breast and colorectal cancer cell lines.

Galmarini CM, Warren G, Kohli E, Zeman A, Mitin A, Vinogradov SV.

Mol Cancer Ther. 2008 Oct;7(10):3373-80. doi: 10.1158/1535-7163.MCT-08-0616.

5.

Hyaluronic acid-based nanogel-drug conjugates with enhanced anticancer activity designed for the targeting of CD44-positive and drug-resistant tumors.

Wei X, Senanayake TH, Warren G, Vinogradov SV.

Bioconjug Chem. 2013 Apr 17;24(4):658-68. doi: 10.1021/bc300632w. Epub 2013 Apr 2.

6.

Comparison of nanogel drug carriers and their formulations with nucleoside 5'-triphosphates.

Vinogradov SV, Kohli E, Zeman AD.

Pharm Res. 2006 May;23(5):920-30. Epub 2006 May 2.

7.

Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models.

Bergman AM, Adema AD, Balzarini J, Bruheim S, Fichtner I, Noordhuis P, Fodstad O, Myhren F, Sandvold ML, Hendriks HR, Peters GJ.

Invest New Drugs. 2011 Jun;29(3):456-66. doi: 10.1007/s10637-009-9377-7. Epub 2010 Jan 12.

8.

Encapsulation of poorly soluble drugs in polymer-drug conjugates: effect of dual-drug nanoformulations on cancer therapy.

Senanayake TH, Lu Y, Bohling A, Raja S, Band H, Vinogradov SV.

Pharm Res. 2014 Jun;31(6):1605-15. doi: 10.1007/s11095-013-1265-3. Epub 2014 Jan 23.

9.

Gemcitabine and γ-cyclodextrin/docetaxel inclusion complex-loaded liposome for highly effective combinational therapy of osteosarcoma.

Sun L, Zhou DS, Zhang P, Li QH, Liu P.

Int J Pharm. 2015 Jan 15;478(1):308-17. doi: 10.1016/j.ijpharm.2014.11.052. Epub 2014 Nov 26.

PMID:
25433201
10.

A novel cytidine analog, RX-3117, shows potent efficacy in xenograft models, even in tumors that are resistant to gemcitabine.

Yang MY, Lee YB, Ahn CH, Kaye J, Fine T, Kashi R, Ohne O, Smid K, Peters GJ, Kim DJ.

Anticancer Res. 2014 Dec;34(12):6951-9.

PMID:
25503121
11.

Polyplex Nanogel formulations for drug delivery of cytotoxic nucleoside analogs.

Vinogradov SV, Zeman AD, Batrakova EV, Kabanov AV.

J Control Release. 2005 Sep 20;107(1):143-57.

12.

Zidovudine, an anti-viral drug, resensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine by inhibition of the Akt-GSK3β-Snail pathway.

Namba T, Kodama R, Moritomo S, Hoshino T, Mizushima T.

Cell Death Dis. 2015 Jun 25;6:e1795. doi: 10.1038/cddis.2015.172.

13.

Oral delivery of taurocholic acid linked heparin-docetaxel conjugates for cancer therapy.

Khatun Z, Nurunnabi M, Reeck GR, Cho KJ, Lee YK.

J Control Release. 2013 Aug 28;170(1):74-82. doi: 10.1016/j.jconrel.2013.04.024. Epub 2013 May 9.

14.

Self-assembled drug delivery systems. Part 8: In vitro/in vivo studies of the nanoassemblies of cholesteryl-phosphonyl gemcitabine.

Li M, Qi S, Jin Y, Dong J.

Int J Pharm. 2015 Jan 15;478(1):124-30. doi: 10.1016/j.ijpharm.2014.11.033. Epub 2014 Nov 15.

PMID:
25448574
15.

Anticancer efficacy of squalenoyl gemcitabine nanomedicine on 60 human tumor cell panel and on experimental tumor.

Reddy LH, Renoir JM, Marsaud V, Lepetre-Mouelhi S, Desmaële D, Couvreur P.

Mol Pharm. 2009 Sep-Oct;6(5):1526-35. doi: 10.1021/mp900099e.

PMID:
19634915
16.

Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents.

Klanova M, Lorkova L, Vit O, Maswabi B, Molinsky J, Pospisilova J, Vockova P, Mavis C, Lateckova L, Kulvait V, Vejmelkova D, Jaksa R, Hernandez F, Trneny M, Vokurka M, Petrak J, Klener P Jr.

Mol Cancer. 2014 Jun 27;13:159. doi: 10.1186/1476-4598-13-159.

17.

Sensitization of human cancer cells to gemcitabine by the Chk1 inhibitor MK-8776: cell cycle perturbation and impact of administration schedule in vitro and in vivo.

Montano R, Thompson R, Chung I, Hou H, Khan N, Eastman A.

BMC Cancer. 2013 Dec 21;13:604. doi: 10.1186/1471-2407-13-604.

18.

Schedule-dependent therapeutic effects of gemcitabine combined with uracil-tegafur in a human pancreatic cancer xenograft model.

Tsujie M, Nakamori S, Nakahira S, Takeda S, Takahashi Y, Hayashi N, Okami J, Nagano H, Dono K, Umeshita K, Sakon M, Monden M.

Pancreas. 2006 Aug;33(2):142-7.

PMID:
16868479
19.

In-vitro and in-vivo anti-cancer activity of a novel gemcitabine-cardiolipin conjugate.

Chen P, Chien PY, Khan AR, Sheikh S, Ali SM, Ahmad MU, Ahmad I.

Anticancer Drugs. 2006 Jan;17(1):53-61. Erratum in: Anticancer Drugs. 2006 Feb;17(2):237.

PMID:
16317290
20.

In vitro and in vivo studies of pharmacokinetics and antitumor efficacy of D07001-F4, an oral gemcitabine formulation.

Hao WH, Wang JJ, Hsueh SP, Hsu PJ, Chang LC, Hsu CS, Hsu KY.

Cancer Chemother Pharmacol. 2013 Feb;71(2):379-88. doi: 10.1007/s00280-012-2017-5. Epub 2012 Nov 10.

PMID:
23143189

Supplemental Content

Support Center